2.50
Hdl Handle:
http://hdl.handle.net/10755/165137
Category:
Abstract
Type:
Presentation
Title:
PREVENTION OF MUCOSITIS IN AUTO BMT/STEM CELL TRANSPLANT PATIENTS
Author(s):
Klocke, Joan; Cannon, Maureen; Gissinger, Diane; Bayer, Ruthee; Devoe, Craig; John, Venna
Author Details:
Joan Klocke, RN, OCN, Assistant Director, North Shore University Hospital, New York, New York, USA, email: jklocke@nshs.edu; Maureen Cannon; Diane Gissinger; Ruthee Bayer; Craig Devoe; Venna John
Abstract:
Topic: It is estimated that 80 percent of patients who undergo high-dose chemotherapy prior to transplantation develop mucositis. Mucositis is a painful complication, which can lead to poor nutrition, increased use of narcotics, dehydration, greater risk for infection and bacteremia and altered quality of life. Patients can have oral ulceration, epigastric discomfort, diarrhea, rectal irritation and bleeding. It is likely that the complications of mucositis can contribute to increased length of stay during stem cell transplantation. Purpose: The purpose of this study is to compare patients who received Kepivance (palifermin) with patients that did not receive this medication regimen during autologous stem cell transplantation. We performed a retrospective analysis of 40 patients; 20 prior to the institution of Kepivance (palifermin), and 20 patients after. The objective of this study was to determine whether the use of Kepivance decreases the incidence and duration of mucositis. Framework: A retrospective comparison study is appropriate for this research. Methods: Data for this study was taken from forty discharged inpatient medical records. No patient identifiers were used, instead a number for each group from 1 to 20 was given. The data collection tool was approved by the Institutional Review Board. A descriptive statistical analysis was performed by an independent statistician. The data points extracted were the following: diagnosis, length of stay, oral mucositis, GI mucositis, narcotics, TPN, antifungals, antidiarrheals and antibiotic use. Findings: The findings of this study support the clinical decision to include Kepivance (palifermin) in the preventive treatment for mucositis in Autologous BMT/Stem Cell Transplant Patients. The average length of stay for non-Kepivance patients was 32.3 days compared to 28.3 days in patients who received the drug. The severity of both oral and GI mucositis appeared to be less. 17 out of 20 non-Kepivance patients experienced diarrhea or rectal irritation versus 9 out of 20 with Kepivance. There was a trend toward earlier engraftment in the Kepivance group. This pilot study suggests an improvement in mucositis symptoms with the use of Kepivance (palifermin). It appears that mucositis and its treatment contribute to the length of stay and costs of stem cell transplantation. Quality of life for these patients can be greatly improved if mucositis is eliminated or reduced during the course of stem cell transplantation.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2006
Conference Name:
31st Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Boston, Massachusetts, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titlePREVENTION OF MUCOSITIS IN AUTO BMT/STEM CELL TRANSPLANT PATIENTSen_GB
dc.contributor.authorKlocke, Joanen_US
dc.contributor.authorCannon, Maureenen_US
dc.contributor.authorGissinger, Dianeen_US
dc.contributor.authorBayer, Rutheeen_US
dc.contributor.authorDevoe, Craigen_US
dc.contributor.authorJohn, Vennaen_US
dc.author.detailsJoan Klocke, RN, OCN, Assistant Director, North Shore University Hospital, New York, New York, USA, email: jklocke@nshs.edu; Maureen Cannon; Diane Gissinger; Ruthee Bayer; Craig Devoe; Venna Johnen_US
dc.identifier.urihttp://hdl.handle.net/10755/165137-
dc.description.abstractTopic: It is estimated that 80 percent of patients who undergo high-dose chemotherapy prior to transplantation develop mucositis. Mucositis is a painful complication, which can lead to poor nutrition, increased use of narcotics, dehydration, greater risk for infection and bacteremia and altered quality of life. Patients can have oral ulceration, epigastric discomfort, diarrhea, rectal irritation and bleeding. It is likely that the complications of mucositis can contribute to increased length of stay during stem cell transplantation. Purpose: The purpose of this study is to compare patients who received Kepivance (palifermin) with patients that did not receive this medication regimen during autologous stem cell transplantation. We performed a retrospective analysis of 40 patients; 20 prior to the institution of Kepivance (palifermin), and 20 patients after. The objective of this study was to determine whether the use of Kepivance decreases the incidence and duration of mucositis. Framework: A retrospective comparison study is appropriate for this research. Methods: Data for this study was taken from forty discharged inpatient medical records. No patient identifiers were used, instead a number for each group from 1 to 20 was given. The data collection tool was approved by the Institutional Review Board. A descriptive statistical analysis was performed by an independent statistician. The data points extracted were the following: diagnosis, length of stay, oral mucositis, GI mucositis, narcotics, TPN, antifungals, antidiarrheals and antibiotic use. Findings: The findings of this study support the clinical decision to include Kepivance (palifermin) in the preventive treatment for mucositis in Autologous BMT/Stem Cell Transplant Patients. The average length of stay for non-Kepivance patients was 32.3 days compared to 28.3 days in patients who received the drug. The severity of both oral and GI mucositis appeared to be less. 17 out of 20 non-Kepivance patients experienced diarrhea or rectal irritation versus 9 out of 20 with Kepivance. There was a trend toward earlier engraftment in the Kepivance group. This pilot study suggests an improvement in mucositis symptoms with the use of Kepivance (palifermin). It appears that mucositis and its treatment contribute to the length of stay and costs of stem cell transplantation. Quality of life for these patients can be greatly improved if mucositis is eliminated or reduced during the course of stem cell transplantation.en_GB
dc.date.available2011-10-27T12:13:11Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:13:11Z-
dc.conference.date2006en_US
dc.conference.name31st Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationBoston, Massachusetts, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.